| Drug General Information |
| Drug ID |
D0I2WQ
|
| Former ID |
DNC009358
|
| Drug Name |
11-Heptanoyloxy-N-n-propylnoraporphine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C26H33NO2
|
| Canonical SMILES |
CCCCCCC(=O)OC1=CC=CC2=C1C3=C4C(C2)N(CCC4=CC=C3)CCC
|
| InChI |
1S/C26H33NO2/c1-3-5-6-7-14-24(28)29-23-13-9-11-20-18-22-25-19(15-17-27(22)16-4-2)10-8-12-21(25)26(20)23/h8-13,22H,3-7,14-18H2,1-2H3/t22-/m1/s1
|
| InChIKey |
KWMUKPVHQQVHLC-JOCHJYFZSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Dopamine D1 receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| 5-hydroxytryptamine 2A receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Morphine addiction
|
|
Alcoholismhsa04020:Calcium signaling pathway
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
PANTHER Pathway
|
Dopamine receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway
|
|
PathWhiz Pathway
|
Dopamine Activation of Neurological Reward System
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (s) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (q) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
SIDS Susceptibility Pathways
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR downstream signaling
|
|
GPCRs, Other
|
| References |
| REF 1 | Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. Epub 2008 Aug 28.N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. |
|---|
